Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice

被引：0
|
作者：
Furuhashi, K. [1 ]
Hataji, O. [1 ]
Nakamura, Y. [1 ]
Suzuki, Y. [1 ]
Sakaguchi, T. [1 ]
Ito, K. [1 ]
Fujiwara, K. [1 ]
Nishii, Y. [1 ]
Taguchi, O. [1 ]
机构：
[1] Matsusaka Municipal Hosp, Resp Ctr, Matsusaka City, Mie, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
chemoradiotherapy; durvalumab; Non-Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.18-19
引用
收藏
页码：S1104 / S1104
页数：1
相关论文
共 50 条
  • [31] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [32] Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
    Jazieh, Khalid
    Khorrami, Mohammadhadi
    Saad, Anas
    Gad, Mohamed
    Gupta, Amit
    Patil, Pradnya
    Viswanathan, Vidya Sankar
    Rajiah, Prabhakar
    Nock, Charles J.
    Gilkey, Michael
    Fu, Pingfu
    Pennell, Nathan A.
    Madabhushi, Anant
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [33] Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis
    Sugimoto, Takeya
    Fujimoto, Daichi
    Sato, Yuki
    Tamiya, Motohiro
    Yokoi, Takashi
    Taniguchi, Yoshihiko
    Hino, Aoi
    Hata, Akito
    Uchida, Junji
    Fukuda, Yasushi
    Hara, Satoshi
    Kanazu, Masaki
    Matsumoto, Hirotaka
    Kokubo, Masaki
    Yamamoto, Nobuyuki
    LUNG CANCER, 2022, 171 : 3 - 8
  • [34] The Clinical Relevance and Management of Grade 2 Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients on Adjuvant Durvalumab
    Moore, R.
    Lau, S.
    Bezjak, A.
    Sacher, A. G.
    Liu, Z.
    Hope, A. J.
    Lok, B.
    Giuliani, M. E.
    Cho, J.
    Sun, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E100 - E100
  • [35] A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer
    Gill, Harpaul S.
    Ramalingam, Suresh S.
    CANCER, 2019, 125 (13) : 2148 - 2153
  • [36] Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer
    Zhang, Hangyue
    Pan, Shiyi
    Li, Tao
    LUNG CANCER, 2023, 183
  • [37] Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
    Wauters, Els
    Vansteenkiste, Johan
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 574 - 577
  • [38] Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
    Thatcher, Nicholas
    Heighway, Jim
    ONCOLOGIST, 2010, 15 (10): : 1034 - 1042
  • [39] Treatment outcome of patients with unresectable stage III non-small cell lung cancer and interstitial pneumonia
    Ogawa, Kazumasa
    Takahashi, Yui
    Murase, Kyoko
    Hanada, Shigeo
    Uruga, Hironori
    Takaya, Hisashi
    Miyamoto, Atsushi
    Morokawa, Nasa
    Kurosaki, Atsuko
    Kishi, Kazuma
    RESPIRATORY INVESTIGATION, 2019, 57 (04) : 388 - 394
  • [40] Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer
    Socinski, MA
    Rosenman, JG
    SEMINARS IN ONCOLOGY, 2005, 32 (02) : S18 - S24
12345